section name header

Basic Information

AUTHOR: Victor I. Reus, MD

Definition

Bipolar disorder is an episodic, recurrent, and frequently progressive condition in which the afflicted individual experiences at least one episode of mania, characterized by at least 1 wk of continuous symptoms of elevated, expansive, or irritable mood, in association with three or more of the following symptoms (four if irritability is the presenting mood):

  • Decreased need for sleep
  • Grandiosity or inflated self-esteem
  • Pressured speech
  • Flight of ideas or subjective sense of racing thoughts
  • Distractibility
  • Increased level of goal-directed activity
  • Problematic behavior with a high potential for painful consequences

Most individuals with bipolar disorder also experience one or more episodes of major depression over their lifetimes or have symptoms of a depressive episode commingled with those of mania (mixed episode). Hypomanic episodes may also occur.1

Synonyms

Manic-depression

Cycloid psychosis

BD

ICD-10CM CODES
F42.0Bipolar affective disorder, current episode hypomanic
F31.1Bipolar affective disorder, current episode manic without psychotic symptoms
F31.2Bipolar affective disorder, current episode manic with psychotic symptoms
F31.3Bipolar affective disorder, current episode mild or moderate depression
F31.4Bipolar affective disorder, current episode severe depression without psychotic symptoms
F31.5Bipolar affective disorder, current episode severe depression with psychotic symptoms
F31.6Bipolar affective disorder, current episode mixed
F31.8Bipolar II disorder
DSM-5 CODE
296.41-296.80Depends on specific diagnosis
Epidemiology & Demographics
Incidence

0.016% to 0.021%

Prevalence (In U.S.)

0.4% to 1.6% (lifetime); bipolar spectrum disorders: 2.8%; approximately 25% attempt suicide, and suicide deaths occur 20× more frequently than in the general population

Predominant Sex

Equal distribution among male and female

Predominant Age

Lifelong condition with age of onset 14 to 30 yr

Peak Incidence

Onset in 20s2

Genetics

  • Concordance rates for monozygotic twins: 0.7 to 0.8; for dizygotic twins: 0.2
  • Risk of affective disorder in offspring with one affected parent with bipolar disorder: 27% to 29%; with two affected parents: 50% to 74%
  • Heritability estimate of 0.85
  • No specific causal mutations have been identified, but cross-disorder studies indicate an overlap with genes associated with a risk for autism or schizophrenia and pleiotropic effects. Genome-wide association analyses and exome sequencing have suggested a role for AKAP11, CACNA1C, ANK3, TRANK1, ODZ4, ZNF804A, and KDM5B, among others, and have implicated ion channelopathies, immune and neuronal signaling, and histone methylation in pathogenesis of bipolar disorder. It is hypothesized that heritability derives from the additive effect of a number of common risk alleles in association with a few higher-risk deleterious variants. Copy number variations and epigenetic factors also moderate risk3,4
Physical Findings & Clinical Presentation

  • Mania associated with:
    1. Psychomotor activation that is usually goal directed but not necessarily productive
    2. Increase in goal-directed activity and excessive involvement in activities leading to unexpected adverse outcomes
    3. Elevated, euphoric, and frequently labile mood
    4. Decreased need for sleep
    5. Flight of ideas with rapid, loud, pressured speech
  • Psychosis often occurs (75%), with delusions, hallucinations, and/or formal thought disorder
  • Depressive episodes resembling major depressive disorder (see “Depression, Major”), although usually of shorter duration and more frequent; atypical features (hypersomnia, prominent anxiety, weight gain) may be present
  • Mixed states, characterized by activation, irritability, and dysphoria, also possible.
Key Diagnostic Criteria Distinguishing Bipolar I Disorder from Bipolar II Disorder:

Manic Episode (Bipolar I Disorder)

  • Distinct period during which there is an abnormally and persistently elevated, expansive, or irritable mood and abnormally and persistently increased goal-directed activity or energy lasting at least 1 wk (or less if hospitalization is required).
  • Must be accompanied by at least three of the following symptoms (four if mood is only irritable): Inflated self-esteem or grandiosity, decreased need for sleep, pressured speech, racing thoughts, distractibility, increased involvement in goal-directed activity or psychomotor agitation, excessive involvement in pleasurable activities with a high potential for painful consequences.
  • Symptoms do not meet criteria for a mixed episode.
  • Disturbance must be sufficiently severe to cause marked impairment in social or occupational functioning or to require hospitalization, or it is characterized by the presence of psychotic features.
  • Symptoms not due to direct physiologic effect of medication, general medication condition, or substance abuse, although if they persist after a direct condition is addressed, a primary bipolar condition should be considered.5

Hypomanic Episode (Bipolar II Disorder)

  • Distinct period during which there is an abnormally and persistently elevated, expansive, or irritable mood and abnormally and persistently elevated activity or energy lasting at least 4 consecutive days.
  • Must be accompanied by at least three of the following symptoms (four if mood is only irritable): Inflated self-esteem or grandiosity, decreased need for sleep, pressured speech, racing thoughts, distractibility, increased involvement in goal-directed activity or psychomotor agitation, excessive involvement in pleasurable activities with a high potential for painful consequences.
  • Hypomanic episodes must be clearly different from the person’s usual nondepressed mood, and there must be a clear change in functioning that is not characteristic of the person’s usual functioning; consider using checklist (HCL-32) for accuracy.
  • Changes in mood and functioning must be observable by others. In contrast to a manic episode, a hypomanic episode is not severe enough to cause marked impairment in social or occupational functioning or to require hospitalization, and there are no psychotic features.
  • Symptoms not due to direct physiologic effect of medication, general medication condition, or substance abuse.
Etiology

Hypotheses:

  • Abnormalities of GABAA and G protein-coupled receptor and membrane function, calcium dysregulation6
  • Alteration of cAMP, MAP kinase, protein kinase C, arachidonic acid cascade, and glycogen synthase kinase-3 signal transduction pathways; mitochondrial dysfunction
  • Alteration in cell survival pathways, glial and neuronal death and loss of neuroplasticity; proposed biomarkers include BDNF and measures of inflammation, oxidative stress, and endothelial function7

Diagnosis

Differential Diagnosis

  • Secondary manias caused by medical disorders (e.g., hyperthyroidism, HIV/AIDS, dementia, stroke and nondominant frontal lobe lesions, Cushing syndrome) or pharmacologic treatment (e.g., steroids, stimulants)
  • First onset of mania after age 50 yr suggestive of secondary mania
  • Less severe, and possibly distinct, conditions of bipolar type II and cyclothymia
  • Comorbid substance abuse or dependency occurs in 60% to 75% of patients and may confound diagnosis and treatment
  • Presentation can be confused with schizophrenia or paranoid psychosis
Workup

  • History
  • Physical examination
  • Mental status examination
  • Mood Disorder Questionnaire (MDQ); Composite International Diagnostic Interview (CIDI) (3.0)
Laboratory Tests

Because of high rate of secondary manias, initial evaluation to confirm health of all major organ systems (routine chemistries, complete blood count, urinalysis, sedimentation rate). A number of biomarkers have been identified but their clinical value is still undetermined.8

Imaging Studies

  • Consider brain imaging if late onset or if neurologic examination is abnormal.
  • Neuroimaging may show evidence of ventricular enlargement or increased white matter hyperintensities; decrements in prefrontal and temporal lobe cortical thickness also reported. Corresponding changes in neurocognition, including changes in executive function, verbal memory, and processing speed, may occur.9

Treatment

Nonpharmacologic Therapy

  • Cognitive-behavioral and family-focused psychoeducational psychotherapy to help patients cope with consequences of the disease, improve adherence with medications, and identify possible environmental triggers; consider life charting.10
  • Bright light therapy in the northern latitudes in individuals exhibiting a seasonal pattern of winter depression.
  • Lifestyle “regularization”; effective sleep hygiene; interpersonal and social rhythm therapy; integrated care management for chronic conditions.11
  • Many smartphone mobile apps for bipolar disorder are available to provide information, help monitor symptoms, and deliver interventions.12
Acute General Rx

  • First-line agents for acute mania and mixed states: Lithium 1500 to 1800 mg/day (0.8 to 1.2 mEq/L), valproate 1000 to 1500 mg/day (50 to 125 ng/ml), carbamazepine 600 to 800 mg/day (4 to 12 μg/ml), oxcarbazepine 900 to 2400 mg/day, olanzapine 10 to 20 mg/day (and olanzapine/samidorphan combination, 10 mg/10 mg), risperidone 2 to 4 mg/day, quetiapine 350 to 800 mg/day, ziprasidone 80 to 120 mg/day, asenapine 10 to 20 mg/day, cariprazine 1.5 to 6 mg/day, or aripiprazole 10 to 30 mg/day. Treatment-resistant cases may respond to varying combinations of these agents or to the addition of clozapine.13,14
  • Useful adjuncts to acute treatment of mania: Benzodiazepines: Lorazepam 1 to 2 mg q4h, clonazepam 1 to 2 mg q4h.
  • Traditional antidepressants can induce manic episodes and exacerbate mania in mixed episodes and may be less effective than in treatment of unipolar depression.
  • First-line options for bipolar depression include lithium, lurasidone, quetiapine, lamotrigine, cariprazine, lumateperone, and olanzapine/fluoxetine combination. Bupropion may have a lower risk for triggering mania, and monoamine oxidase inhibitors or electroconvulsive therapy may be efficacious in treatment-resistant cases. Off-label agents with possible efficacy include modafinil, pramipexole, and intravenous ketamine. rTMS has received an FDA breakthrough device designation for treatment of bipolar depression, although data are still limited.
Chronic Rx

  • Goal of long-term treatment: Prevention of relapse or episode recurrence.
  • Best agents for prophylaxis of mania: Lithium (0.4 to 0.8 mEq/L), quetiapine, aripiprazole, and olanzapine (valproate, carbamazepine/oxcarbazepine possibly beneficial).
  • Best agents for prophylaxis of depression: Lamotrigine and lithium.
  • Risk/benefit of atypical antipsychotics vs. traditional mood stabilizers in maintenance unclear. Long-acting injectables may have added benefit in cases of poor adherence.
  • Long-term use of antidepressants: Frequently destabilizes patient and leads to more frequent relapses; depression outweighs mania as the most debilitating dimension over the lifespan; bipolar disorder accounts for 7% of all disease-related disability-adjusted life years.
Disposition

  • Course is variable.
  • More than 90% of patients having a single manic episode are likely to experience others.
  • Uncontrolled manic or depressive episodes can lead to additional episodes.
  • Lithium, in comparison to other mood stabilizers or atypical antipsychotic agents, has been shown to specifically decrease suicidal risk.
  • Socioeconomic consequences of both mania and depression can be severe and disabling. Bipolar disorder is the most costly mental health condition for commercial insurers nationwide.15
  • Mortality rate from all causes is 15× that of the general population.
Referral

  • If use of antidepressant contemplated or in cases of pediatric bipolar disorder
  • If patient is severely manic, rapid cycling, pregnant, or suicidal or is in a bipolar, mixed episode16

Pearls & Considerations

Comments

  • All patients presenting with depression should be asked about past personal and family history of mania and hypomania; 70% of bipolar patients have previously been misdiagnosed. Onset before age 25, postpartum onset, and poor prior response to antidepressants are additional clues.
  • Prompt recognition of the earliest signs of mania in a given individual (e.g., decreased need for sleep, increased rate of speech) allows earlier intervention and a better likelihood of preventing a full episode.
  • Bipolar disorder in children frequently manifests as episodic behavioral disinhibition, affective lability, and temper dysregulation, but current consensus indicates that the condition is overdiagnosed in this age group. Disruptive mood dysregulation disorder (DMDD) describes children who exhibit persistent irritability and severe temper outbursts on a frequent basis (at least three times/wk for a year or more).
  • Rapid cycling (greater than three episodes/year) and mixed states are associated with a poorer prognosis, including a longer course, more treatment resistance, more substance use comorbidity, and increased suicidal risk.
  • Patients treated with atypical antipsychotic agents should be carefully monitored for development of metabolic syndrome. Independent of medication effect, there is a higher prevalence of metabolic syndrome and abdominal obesity in those with bipolar disorder.
  • Despite some variation in prevalence, the severity, impact, and patterns of comorbidity of bipolar disorder are similar in different countries in world health surveys.
  • Bipolar disorder often cooccurs with anxiety disorders and attention deficit hyperactivity disorder (ADHD), making attribution of specific symptoms difficult.
  • Patients receiving anticonvulsants or antidepressants should be monitored for a possible increase in suicidal thoughts or behavior.
  • There is preliminary evidence that nutraceutical agents like omega-3 fatty acids and N-acetyl cysteine (NAC) may have efficacy in the treatment of bipolar disorder.
  • Multiple studies show a correlation between bipolar disorder and heightened creativity.
  • Patients with bipolar disorder are at risk for catatonic syndrome, including manic delirium.
Patient & Family Education

Information available at http://www.NMHA.org/ and http://www.dbsalliance.org/.

Related Content

Bipolar Disorder (Patient Information)

Depression, Major (Related Key Topic)

Related Content

    1. Bauer MS: Bipolar disorder, Ann Int Med 175(7):ITC 97, 2022.
    2. Bolton S. : Bipolar disorder: trimodal age-at-onset distributionBipolar Disord. ;23(4), 2021.
    3. Mullins N. : Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biologyNat Genet. ;53(6), 2021.
    4. Grotzinger A.D. : Genetic architecture of 11 major psychiatric disorders at biobehavioral, functional genomic and molecular genetic levels of analysisNat Genet. ;54(5), 2022.
    5. Carvalho A.F. : Bipolar disorderN Engl J Med. ;383(1), 2021.
    6. Mokhtari A. : The molecular pathophysiology of mood disorders: from the analysis of single layers to multi-omic integrationProg Neuropsychopharmacol Bio Psychiatry. ;116, 2022.
    7. Magioncalda P., Martino M. : A unified model of the pathophysiology of bipolar disorderMol Psychiatry. ;27(1), 2022.
    8. Vega-Nunez A. : Clinical value of inflammatory and neurotrophic biomarkers in bipolar disorder: a systematic review and meta-analysisBiomedicines. ;10(6), 2022.
    9. Luna L.P. : A systematic review and meta-analysis of structural and functional brain alterations in individuals with genetic and clinical high-risk for psychosis and bipolar disorderProg Neuropsyhopharmacol Bio Psychiatry. ;117, 2022.
    10. Tsapekos D. : Towards personalizing cognitive remediation therapy: examining moderators of response for euthymic people with bipolar disorderBehav Res Ther. ;151, 2022.
    11. Moot W. : Domain-based functional improvements in bipolar disorder after interpersonal and social rhythm therapyFront Psychiatry. ;13, 2022.
    12. Nature Genetics Tajika A. : Mood stabilizers and antipsychotics for acute mania: systematic review and meta-analysis of augmentation therapy versus monotherapy from the perspective of time to the onset of treatment effectsInt J Neuropsychopharmacol. ;25(10):839-852, 2022.https://doi.10.1093/ijnp/pyac050
    13. Fountoulakis K.N. : Lithium treatment of bipolar disorder in adults: a systematic review of randomized trials and meta-analysesEur Neuropsychopharmacol. ;54, 2022.
    14. Bauer M.S. : In the clinic, bipolar disorder ITC98-109 Ann Intern Med. ;175(7), July 2022.
    15. Masters G.A. : Prevalence of bipolar disorder in perinatal women: a systematic review and meta-analysisJ Clin Psychiatry. ;83(5), 2022.
    16. Xu Z. : A predictive model of risk factors for conversion from depressive disorder to bipolar disorder based on clinical characteristics and circadian gene polymorphismsFront Psychiatry. ;13, 2022.